Hindustan Bio Sciences Limited has announced its unaudited financial results for the quarter ended December 31, 2025, demonstrating a significant turnaround with a profit of ₹8.20 lakhs. The Hyderabad-based pharmaceutical company's Board of Directors approved these results during their meeting held on January 31, 2026, at the registered office located at Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad.

Financial Performance Overview

The company's Q3FY26 performance shows a marked improvement compared to recent quarters. Total income from operations reached ₹40.03 lakhs, comprising revenue from operations of ₹1.78 lakhs and other income of ₹38.25 lakhs. This represents a substantial increase from the previous quarter where total income was only ₹0.86 lakhs.

Expense Management

Total expenses for Q3FY26 stood at ₹31.64 lakhs, with other expenses being the largest component. The expense breakdown shows varied performance across different categories, with some items showing negative values indicating adjustments or reversals from previous periods.

Nine-Month Performance

For the nine-month period ended December 31, 2025, Hindustan Bio Sciences reported positive results with a profit of ₹3.74 lakhs compared to a loss of ₹0.98 lakhs in the corresponding period of the previous year. Total income for the nine-month period reached ₹74.39 lakhs against ₹42.20 lakhs in the previous year.

Earnings Per Share

The company's earnings per share (EPS) for Q3FY26 stood at ₹0.08 for both basic and diluted calculations, compared to negative ₹0.06 in the previous quarter and negative ₹0.04 in Q3FY25. The paid-up equity capital remains constant at ₹205.02 lakhs with a face value of ₹2 per share.

Board Approval and Compliance

The unaudited financial results were formally approved by the Board of Directors during their meeting on January 31, 2026, which commenced at 2:00 PM and concluded at 3:30 PM. The meeting was held at the company's registered office in Banjara Hills, Hyderabad. Managing Director Venkata Rama Mohan Raju Jampana signed off on the results, ensuring compliance with Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The results were subject to a limited review by VASG & Associates, Chartered Accountants, who provided an independent auditor's review report confirming that the financial statements comply with applicable accounting standards and disclosure requirements.

Hindustan bio sciences Limited has filed a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, reporting the acquisition of shares by Bosco Armando Menezes and Emily Bosco Menezes on January 23, 2026.

Share Acquisition Details

The acquisition involved the purchase of 15,000 shares through open market transactions on January 22, 2026. The acquirers, Bosco Armando Menezes and Emily Bosco Menezes, are not part of the promoter group of the company.

Shareholding Pattern Changes

Prior to this acquisition, the combined holding of both acquirers stood at 5,10,000 shares, representing 4.98% of the total voting capital. The recent purchase has increased their combined shareholding to 5,25,000 shares, representing 5.12% of the company's total voting capital.

Individual Shareholding Breakdown

The disclosure reveals the individual shareholding pattern of both acquirers. Bosco Armando Menezes and Emily Bosco Menezes each held 2,55,000 shares before the acquisition. After the purchase, their combined voting rights increased to 2,70,000 shares, while maintaining 2,55,000 shares in encumbered form.

Company Capital Structure

The company's equity share capital remains unchanged following this transaction. Hindustan Bio Sciences Limited maintains its equity share capital at Rs.2,05,01,600, consisting of 1,02,50,800 equity shares of Rs.2 each. The company's shares are listed on BSE Limited.

The disclosure was signed by J V R Mohan Raju, Managing Director of Hindustan Bio Sciences Limited, and filed with BSE Limited on January 23, 2026, in compliance with SEBI regulations for substantial acquisition of shares.